R224
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 74
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.320
- MITOTIC_SPINDLE+0.310
- MYC_TARGETS_V2+0.290
- PI3K_AKT_MTOR_SIGNALING+0.240
- DNA_REPAIR+0.170
- MYC_TARGETS_V1+0.170
- UNFOLDED_PROTEIN_RESPONSE+0.170
- G2M_CHECKPOINT+0.150
- OXIDATIVE_PHOSPHORYLATION+0.150
- ANDROGEN_RESPONSE+0.120
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- INFLAMMATORY_RESPONSE-0.430
- ANGIOGENESIS-0.420
- ALLOGRAFT_REJECTION-0.400
- INTERFERON_ALPHA_RESPONSE-0.360
- IL6_JAK_STAT3_SIGNALING-0.340
- INTERFERON_GAMMA_RESPONSE-0.330
- PANCREAS_BETA_CELLS-0.320
- TNFA_SIGNALING_VIA_NFKB-0.320
- CHOLESTEROL_HOMEOSTASIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR26320097 | — | — | 0.896 |
| 2 | MDT-AP-1353 | Med | Medulloblastoma | 0.887 |
| 3 | MDT-AP-0211 | Med | Medulloblastoma | 0.885 |
| 4 | SRR26320084 | — | — | 0.878 |
| 5 | TCGA-56-A4BY-01A-11R-A24H-07 | — | cohortSQ2 | 0.866 |
| 6 | SRR660812 | GTEX | — | 0.866 |
| 7 | MDT-AP-0188 | Med | Medulloblastoma | 0.863 |
| 8 | 15d39440-6bb8-4ecb-add1-9ae8b007dc70 | — | — | 0.861 |
| 9 | SRR1797243 | — | cohortSC | 0.859 |
| 10 | SRR8943005 | — | — | 0.856 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.030 | Inavolisib | — uncovered |